Cargando…

Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients

Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) therapy has become increasingly used and established in many hospitals as a routine treatment. With ECMO-therapy being a resource-demanding procedure, it is of interest whether a more prolonged VV-ECMO treatment would hold sufficient therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Flinspach, Armin N., Raimann, Florian J., Bauer, Frederike, Zacharowski, Kai, Ippolito, Angelo, Booke, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094941/
https://www.ncbi.nlm.nih.gov/pubmed/37048583
http://dx.doi.org/10.3390/jcm12072499
_version_ 1785023961953730560
author Flinspach, Armin N.
Raimann, Florian J.
Bauer, Frederike
Zacharowski, Kai
Ippolito, Angelo
Booke, Hendrik
author_facet Flinspach, Armin N.
Raimann, Florian J.
Bauer, Frederike
Zacharowski, Kai
Ippolito, Angelo
Booke, Hendrik
author_sort Flinspach, Armin N.
collection PubMed
description Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) therapy has become increasingly used and established in many hospitals as a routine treatment. With ECMO-therapy being a resource-demanding procedure, it is of interest whether a more prolonged VV-ECMO treatment would hold sufficient therapeutic success. Our retrospective study included all VV-ECMO runs from 1 January 2020 to 31 June 2022. We divided all runs into four groups (<14 days, 14–27, 28–49, 50+) of different durations and looked for differences overall in hospital survival. Additionally, corresponding treatments and therapeutic modalities, as well as laboratory results, were analyzed. We included 117 patients. Of those, 97 (82.9%) received a VV-ECMO treatment longer than two weeks. We did not find a significant association between ECMO duration (p = 0.15) and increased mortality though a significant correlation between the patients’ age and their probability of survival (p = 0.02). Notably, we found significantly lower interleukin-6 levels with an increase in therapy duration (p < 0.01). Our findings show no association between the duration of ECMO therapy and mortality. Thus, the treatment duration alone may not be used for making assumptions about the prospect of survival. However, attention is also increasingly focused on long-term outcomes, such as post-intensive care syndrome with severe impairments.
format Online
Article
Text
id pubmed-10094941
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100949412023-04-13 Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients Flinspach, Armin N. Raimann, Florian J. Bauer, Frederike Zacharowski, Kai Ippolito, Angelo Booke, Hendrik J Clin Med Article Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) therapy has become increasingly used and established in many hospitals as a routine treatment. With ECMO-therapy being a resource-demanding procedure, it is of interest whether a more prolonged VV-ECMO treatment would hold sufficient therapeutic success. Our retrospective study included all VV-ECMO runs from 1 January 2020 to 31 June 2022. We divided all runs into four groups (<14 days, 14–27, 28–49, 50+) of different durations and looked for differences overall in hospital survival. Additionally, corresponding treatments and therapeutic modalities, as well as laboratory results, were analyzed. We included 117 patients. Of those, 97 (82.9%) received a VV-ECMO treatment longer than two weeks. We did not find a significant association between ECMO duration (p = 0.15) and increased mortality though a significant correlation between the patients’ age and their probability of survival (p = 0.02). Notably, we found significantly lower interleukin-6 levels with an increase in therapy duration (p < 0.01). Our findings show no association between the duration of ECMO therapy and mortality. Thus, the treatment duration alone may not be used for making assumptions about the prospect of survival. However, attention is also increasingly focused on long-term outcomes, such as post-intensive care syndrome with severe impairments. MDPI 2023-03-25 /pmc/articles/PMC10094941/ /pubmed/37048583 http://dx.doi.org/10.3390/jcm12072499 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Flinspach, Armin N.
Raimann, Florian J.
Bauer, Frederike
Zacharowski, Kai
Ippolito, Angelo
Booke, Hendrik
Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients
title Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients
title_full Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients
title_fullStr Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients
title_full_unstemmed Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients
title_short Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients
title_sort therapy and outcome of prolonged veno-venous ecmo therapy of critically ill ards patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094941/
https://www.ncbi.nlm.nih.gov/pubmed/37048583
http://dx.doi.org/10.3390/jcm12072499
work_keys_str_mv AT flinspacharminn therapyandoutcomeofprolongedvenovenousecmotherapyofcriticallyillardspatients
AT raimannflorianj therapyandoutcomeofprolongedvenovenousecmotherapyofcriticallyillardspatients
AT bauerfrederike therapyandoutcomeofprolongedvenovenousecmotherapyofcriticallyillardspatients
AT zacharowskikai therapyandoutcomeofprolongedvenovenousecmotherapyofcriticallyillardspatients
AT ippolitoangelo therapyandoutcomeofprolongedvenovenousecmotherapyofcriticallyillardspatients
AT bookehendrik therapyandoutcomeofprolongedvenovenousecmotherapyofcriticallyillardspatients